ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 647,09
0,49%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Fate Therapeutics Inc (FATE)

  7. Fate Therapeutics Inc (FATE) Actualités

FATE

Fate Therapeutics (FATE)

Fate Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FATE
DateHeureSourceTitreSymboleSociété
07/06/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
04/06/202422h01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
29/05/202422h01GlobeNewswire Inc.Fate Therapeutics to Present at 2024 Jefferies Global Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
09/05/202422h01GlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
09/05/202414h30GlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
06/05/202414h00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
03/05/202422h30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
22/04/202422h30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
03/04/202414h00GlobeNewswire Inc.Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
02/04/202422h01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
19/03/202413h44GlobeNewswire Inc.Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementNASDAQ:FATEFate Therapeutics Inc
05/03/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
04/03/202419h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
01/03/202414h00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
26/02/202422h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FATEFate Therapeutics Inc
26/02/202422h01GlobeNewswire Inc.Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
13/02/202400h06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
08/01/202414h00GlobeNewswire Inc.Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid TumorsNASDAQ:FATEFate Therapeutics Inc
13/12/202323h00GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
28/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FATEFate Therapeutics Inc
08/11/202322h44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:FATEFate Therapeutics Inc
08/11/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FATEFate Therapeutics Inc
08/11/202322h01GlobeNewswire Inc.Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
25/10/202314h00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
31/08/202314h00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
08/08/202322h01GlobeNewswire Inc.Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
28/07/202314h00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
15/06/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FATEFate Therapeutics Inc
08/06/202322h13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FATEFate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FATE

Dernières Valeurs Consultées

EU
LR
Legrand
EU
DG
Vinci
EU
SGO
Cie de SaintGobain
EU
CS
Axa
EU
RI
Pernod Ricard
EU
EN
Bouygues
EU
HO
Thales
EU
BN
Danone
EU
PX1
CAC 40
EU
BNP
BNP Paribas
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
NYSE
MRK
Merck
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés